Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
There have been reports suggesting that continuous administration of epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs) is advantageous for patients in which gradual
disease progression was observed after the establishment of clinical benefit from EGFR-TKIs.
However, whether EGFR TKI with or without chemotherapy provides more survival benefit has not
been formally evaluated.